Portolano Cavallo

Life Sciences

Blog

Portolano Cavallo Life Sciences Blog
18 Sep
The Italian Competition Authority launches an investigation into suspected pay-for-delay agreements between 8 pharma companies concerning a biosimilar drug (Biogen / Samsung / Genentech...)
On May 21, 2024, the Italian Competition Authority (the AGCM or ICA) opened new proceedings against eight pharmaceutical companies to investigate suspected pay-for-delay practices in breach of the prohibition on anti-competitive agreements (Article 101 TFEU).
17 Sep
The Italian Council of State upholds the Competition Authority’s €3.2M fine for abuse of dominance by negotiating an unjustifiably high reimbursement price for an “orphan” drug (Leadiant Biosciences)
With judgement No. 2967 of March 29, 2024, The Council of State [1] (Italy’s top administrative court) upheld a fine against the pharmaceutical group Leadiant (“Leadiant”) by the Italian Competition Authority (the AGCM or the “ICA”) for abuse of a dominant position pursuant to Article 102 of the Treaty on the Functioning of the European Union (TFEU).
1 Jul
Pfizer ordered to pay damages to the National Health System for abusing a dominant position in managing the Xalatan patent lifecycle
From 2012 to 2014, Pfizer Italia S.r.l., Pfizer Health A.B., and Pfizer Inc. and Ratiopharm Italia S.r.l. locked horns in litigation before the AGCM and the Italian administrative court.
12 Jun
How Digital Procurement Platforms (PADs) change procurement
Among the main types of infrastructure needed to achieve full digitization of public procurement are Digital Procurement Platforms, or “PADs.” On January 1, 2024, the provisions of the new Public Procurement Code on the digitization of tender procedures became fully effective.
Welcome to the Portolano Cavallo Life Sciences blog focusing on legal development and key legal issues affecting the Life Sciences-Healthcare industry.
...
Read more
Our highly-ranked team of professionals will provide news, insights and multidisciplinary commentary on the hottest and most recent regulatory, transactional and contentious aspects of the pharmaceutical, bio-tech, med-tech, food supplement and healthcare world with an eye on its digital transformation and technological developments.

This blog will be a place for focusing on digital health, telemedicine and artificial intelligence, as well as more traditional topics: from the protection of intellectual properties to performance of clinical trials, from the market access to advertising and competition issues, from internal and criminal investigations to M&A and Venture Capital transactions.

Close
October 6, 2023
CBD products: the Administrative Court suspended until October 24 the recent Decree of the Italian Ministry of Health listing cannabidiol for oral use among narcotic drugs, due to the lack o...
October 4, 2023
The Guidelines for regulating contractual relations between universities and research institutes and private sponsors were adopted by the relevant Italian Ministries following the amendment ...
September 21, 2023
CBS products: from September 20th, compositions for oral administration of cannabidiol obtained from Cannabis sativa extracts shall be considered as narcotic drugs in Italy, as they have bee...
July 27, 2023
Payback on medical devices: Italian government announces extension of payment deadline to October 30, 2023
July 21, 2023
On July 21, 2023, the Italian Ministry of Health published new guidelines on health advertising of self-medication drugs (OTC) and non-prescription drugs (SOP), including advertising on new ...
Search by...
Search
Follow us on
Follow us on